Micro Emerging Active

LEGN nears adjusted profitability with CARVYKTI growth

New narrative with limited coverage — still forming.

Score
0.2
Velocity
▲ 0.0
Articles
4
Sources
1

Top Movers

TickerSectorChange
B
Materials+14.5%
LEGN
Healthcare+5.4%
T
Telecommunication+4.6%
CAR
Industrials+4.3%

Sentiment Timeline

Sector Performance

Stock Performance

Event Timeline

Aug 12, 2026
Legend Biotech shares rise 5% as Q2 earnings and revenue beat estimates Bullish
Jun 25, 2026
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical … Bullish
Jun 04, 2026
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results Bullish
May 30, 2026
Legend Biotech (LEGN) Nears Adjusted Profitability This Year Amid Continued CARVYKTI Growth Neutral

Related Articles

Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results

Yahoo Finance · Jun 04, 2026
Mixed
🤖

AI Overview

What happened: Legend Biotech Corporation (LEGN) shares surged 42% on June 3, 2023, following promising results from its cancer therapy candidate, LB5006. UBS raised its price target to $49, reflecting confidence in the drug's potential. LEGN, now among the top healthcare stocks, is nearing adjusted profitability this year, driven by strong sales of its CARVYKTI treatment.

Market impact: The biotech sector, particularly cancer therapy-focused companies, is affected. LEGN's success could attract investors to similar biotechs with promising pipelines. Competitors like Amgen (AMGN) and Bristol-Myers Squibb (BMY) may face increased pressure to deliver strong clinical data.

What to watch next: LEGN's upcoming earnings on August 15, 2023, will provide insights into CARVYKTI's growth trajectory and potential profitability. Additionally, watch for updates on LB5006's clinical progress, with a Phase 2 study expected to commence in H2 2023.
AI Overview as of Jun 25, 2026

Timeline

First SeenAug 12, 2026
Last UpdatedAug 22, 2026